ESC Premium Access

Targeting SGLT2 in clinical cardiology: discussing the benefits in cardiovascular risk, diabetes & heart failure

Event: ESC Congress 2018
Topic: Risk Factors and Prevention
Session type: Satellite Symposium - Experts on the Spot
Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Boehringer Ingelheim/Lilly
Date: 27 August 2018
Time: 16:00 - 16:30

Session

3 presentations in this session

Introduction - Targeting SGLT2 in clinical cardiology: discussing the benefits in cardiovascular risk, diabetes & heart failure.

Speaker: Professor F. Cosentino (Stockholm, SE)
Thumbnail

Targeting SGLT2 inhibition in cardiology: what is the profile of benefit?

Speaker: Professor N. Marx (Aachen, DE)
Thumbnail

Panel discussion: discussing the benefits in cardiovascular risk, diabetes & heart failure.

Speaker: Professor S. Jacob (Villingen, DE)
Speaker: Professor N. Marx (Aachen, DE)
Speaker: Professor F. Cosentino (Stockholm, SE)
Speaker: Professor J. Deanfield (London, GB)
Thumbnail

6 speakers from this session

Professor Francesco Cosentino

Unit of Cardiology, Karolinska Institute & Karolinska University Hospital, Stockholm (Sweden)
22 presentations
0 follower

Professor Nikolaus Marx

RWTH University Hospital Aachen, Aachen (Germany)
26 presentations
0 follower

Professor Stephan Jacob

, Villingen (Germany)
6 presentations
0 follower

Professor Nikolaus Marx

RWTH University Hospital Aachen, Aachen (Germany)
26 presentations
0 follower

Professor Francesco Cosentino

Unit of Cardiology, Karolinska Institute & Karolinska University Hospital, Stockholm (Sweden)
22 presentations
0 follower

Professor John Eric Deanfield

University College London, London (United Kingdom of Great Britain & Northern Ireland)
36 presentations
1 follower

This platform is supported by

logo Novo Nordisk